Drug Trial Radar · NCT01822808
Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure
Last checked: Nov 20, 2026Latest source record: Aug 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
500
Planned (sponsor's estimate)
Start
Jan 2013
Primary completion
Jan 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- University of Cape TownAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Momentum Research, Inc.
- First posted
- Apr 2, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To investigate the effect of hydralazine isosorbide dinitrate on clinical outcomes, symptoms, cardiac parameters and functional status of African patients hospitalized with AHF and left ventricular dysfunction during 24 weeks of therapy. Administration of hydralazine/nitrates will be superior to placebo administration in reducing HF readmission or death, improving dyspnoea, reducing blood pressure and brain natriuretic peptide (BNP) in African patients admitted with AHF and left ventricular dysfunction.
Conditions
- Acute Heart Failure
- Left Ventricular Dysfunction
Interventions
HydralazineDrug
Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
Isosorbide DinitrateDrug
Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to death or HF re-admissionTime frame: through to day 180
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hatter Institute for Cardiovascular Research in Africa
Cape Town, Western Cape, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.